[Phase I study of S-1. S-1 Study Group].

@article{Taguchi1997PhaseIS,
  title={[Phase I study of S-1. S-1 Study Group].},
  author={Tetsuo Taguchi and Yukio Inuyama and Ryunosuke Kanamaru and Kazuo Hasegawa and Shugo Akazawa and Hisanobu Niitani and Hisashi Furue and Minoru Kurihara and Keiichiro Ota and Shoji Suga and Yutaka Ariyoshi and Shinichiro Takai and Takashi Shimoyama and Tesuya Toge and Shigemitsu Takashima and Keishi Sugimachi and Yusuke Hara and Hiroyuki Fujita and Kengo Kimura and Tsuyoshi Saito and Shigeru Tsukagoshi and Ikko Nakao},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={1997},
  volume={24 15},
  pages={2253-64}
}
We have conducted Phase I study of a novel oral antitumor agent of fluorinated pyrimidines, S-1, in which tegafur (FT) is combined with two classes of modulator, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) at a molar ratio of FT:CDHP:Oxo = 1:0.4:1 as a multi-center study with 16 institutions nationwide. Two administration methods, once and twice daily administrations, were evaluated. As a result, MAD was determined as 150 mg/body/day approximately 200 mg/body/day and 75 mg… CONTINUE READING